The role of surgery in the management of patients with platinum-sensitive recurrent ovarian cancer: Survey among Dutch gynecologists and medical oncologists

Gynecologic Oncology

Volumn 131, Issue 3, 2013, Pages 561-566

  Van De Laar, Rafli ^a,b,c   Zusterzeel, Petra L M ^a   Van Gorp, Toon ^b,c   Ottevanger, Petronella B ^a   Massuger, Leon F A G ^a   Kruitwagen, Roy F P M ^b,c  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^c MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Recurrent ovarian cancer; Secondary cytoreductive surgery

Indexed keywords

CARBOPLATIN; CISPLATIN; PACLITAXEL;

ARTICLE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; FEMALE; GYNECOLOGIST; HEALTH SURVEY; HUMAN; LAPAROSCOPY; MEDICAL ONCOLOGIST; NETHERLANDS; OVARY CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUESTIONNAIRE;

RECURRENT OVARIAN CANCER; SECONDARY CYTOREDUCTIVE SURGERY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ATTITUDE OF HEALTH PERSONNEL; CARBOPLATIN; CHEMOTHERAPY, ADJUVANT; CISPLATIN; CLINICAL TRIALS, PHASE III AS TOPIC; DATA COLLECTION; FEMALE; GYNECOLOGY; HUMANS; MEDICAL ONCOLOGY; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, GLANDULAR AND EPITHELIAL; NETHERLANDS; OVARIAN NEOPLASMS; PACLITAXEL; QUESTIONNAIRES; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84888292156     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2013.09.016     Document Type: Article

References (21)

1. J.A. Ledermann, and F.A. Raja Clinical trials and decision-making strategies for optimal treatment of relapsed ovarian cancer Eur J Cancer 47 2011 S104 S115
2. M.K. Parmar, J.A. Ledermann, N. Colombo, A. du Bois, J.F. Delaloye, and G.B. Kristensen Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial Lancet 361 2003 2099 2106
3. J. Pfisterer, I. Vergote, A. Du Bois, and E. Eisenhauer Combination therapy with gemcitabine and carboplatin in recurrent ovarian cancer Int J Gynecol Cancer 15 Suppl. 1 2005 36 41
4. C. Aghajanian, S.V. Blank, B.A. Goff, P.L. Judson, M.G. Teneriello, and A. Husain OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer J Clin Oncol 30 2012 2039 2045
5. R.E. Bristow, I. Puri, and D.S. Chi Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis Gynecol Oncol 112 2009 265 274
6. K. Galaal, R. Naik, R.E. Bristow, A. Patel, A. Bryant, and H.O. Dickinson Cytoreductive surgery plus chemotherapy versus chemotherapy alone for recurrent epithelial ovarian cancer Cochrane Database Syst Rev 2010 CD007822
7. M. Friedlander, E. Trimble, A. Tinker, D. Alberts, E. Avall-Lundqvist, and M. Brady Clinical trials in recurrent ovarian cancer Int J Gynecol Cancer 21 2011 771 775
8. G. Eysenbach Improving the quality of Web surveys: the Checklist for Reporting Results of Internet E-Surveys (CHERRIES) J Med Internet Res 6 2004 e34
9. P. Harter, A. du Bois, M. Hahmann, A. Hasenburg, A. Burges, and S. Loibl Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial Ann Surg Oncol 13 2006 1702 1710
10. S.J. Chang, M. Hodeib, J. Chang, and R.E. Bristow Survival impact of complete cytoreduction to no gross residual disease for advanced-stage ovarian cancer: a meta-analysis Gynecol Oncol 130 3 2013 493 498
11. D. Lorusso, M. Mancini, R. Di Rocco, R. Fontanelli, and F. Raspagliesi The role of secondary surgery in recurrent ovarian cancer Int. J. Surg. Oncol. 2012 2012 1 6
12. P. Harter, J. Sehouli, A. Reuss, A. Hasenburg, G. Scambia, and D. Cibula Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO Int J Gynecol Cancer 21 2011 289 295
13. W.J. Tian, D.S. Chi, J. Sehouli, C.G. Trope, R. Jiang, and A. Ayhan A risk model for secondary cytoreductive surgery in recurrent ovarian cancer: an evidence-based proposal for patient selection Ann Surg Oncol 19 2012 597 604
14. S.M. Lenhard, A. Burges, T.R. Johnson, A. Kirschenhofer, C. Bruns, and R. Linke Predictive value of PET-CT imaging versus AGO-scoring in patients planned for cytoreductive surgery in recurrent ovarian cancer Eur J Obstet Gynecol Reprod Biol 140 2008 263 268
15. P. Benedetti Panici, A. De Vivo, F. Bellati, N. Manci, G. Perniola, and S. Basile Secondary cytoreductive surgery in patients with platinum-sensitive recurrent ovarian cancer Ann Surg Oncol 14 2007 1136 1142
16. M.J. Rutten, K.N. Gaarenstroom, T. Van Gorp, H.S. van Meurs, H.J. Arts, and P.M. Bossuyt Laparoscopy to predict the result of primary cytoreductive surgery in advanced ovarian cancer patients (LapOvCa-trial): a multicentre randomized controlled study BMC Cancer 12 2012 31
17. L. Woelber, S. Jung, C. Eulenburg, V. Mueller, J. Schwarz, and F. Jaenicke Perioperative morbidity and outcome of secondary cytoreduction for recurrent epithelial ovarian cancer Eur J Surg Oncol 36 2010 583 588
18. F. Vernooij, A.P. Heintz, J.W. Coebergh, L.F. Massuger, P.O. Witteveen, and Y. van der Graaf Specialized and high-volume care leads to better outcomes of ovarian cancer treatment in the Netherlands Gynecol Oncol 112 2009 455 461
19. R.E. Bristow, B.E. Palis, D.S. Chi, and W.A. Cliby The National Cancer Database report on advanced-stage epithelial ovarian cancer: impact of hospital surgical case volume on overall survival and surgical treatment paradigm Gynecol Oncol 118 2010 262 267
20. E.J. Tanner, D.S. Chi, E.L. Eisenhauer, T.P. Diaz-Montes, A. Santillan, and R.E. Bristow Surveillance for the detection of recurrent ovarian cancer: survival impact or lead-time bias? Gynecol Oncol 117 2010 336 340
21. A.G. van der Zee, N. Colombo, G. Gitsch, N. Reed, F. Amant, and D. Cibula ESGO statement on the role of CA-125 measurement in follow-up of epithelial ovarian cancer Int J Gynecol Cancer 22 2012 175